| Plasma, as a major component of blood, plays important physiological functions. Plasma proteins would take place some quality and quantity changes when suffering from pathological damages of human body. Detecting these characteristic changes is critical for disease diagnosis and therapeutic monitoring. At the same times, plasma is a complicated and dynamic changed system, consists of different kind and abundant proteins, which bring out many difficulties for the plasma research. The development of proteomic technologies and the beginning of Human Plasma Proteome Project (HPPP) provide favorable platforms to understand plasma proteins in healthy and sick states.Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in China and lack of effective early diagnostic methods. This study choose different proteomic technology to separate and identify ESCC associated secreted proteins/peptides biomarkers. First, Sera from ESCC patients were used to recognize tumor associated antigens from ESCC tissues or cell lines. The enriched candidate proteins were separated by SDS-PAGE and identified by the liquid chromatography-tandem mass spectrometry (LC-MS/MS). The expression of Ku70 protein was verified by Western blot and immunohistochemistry, and found significantly up-regulated in ESCC tissues and serum, ku70 might become a candidate serum biomarker of ESCC. Therefore, the serum from tumor patients could act as molecular probes to recognize and enrich tumor associated proteins, which combined proteomic separated and identified technology was a new approach to found humoral tumor candidate biomarkers. Clusterin was a new secreted serum candidate biomarker for ESCC identified by 2DE-MALDI-TOF-TOF technology in ESCC serum comparative proteomic study, which was found significantly reduced or lost in ESCC serum and tissues. The changes of different truncated...
|
PDF Full Text Request